Monograph Title | Section | Source Publication Sort descending | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
<621> CHROMATOGRAPHY | ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS | USPNF Online | Online | 26-Aug-2022 | 1-Dec-2022 | NA | NA | In Liquid Chromatography: Isocratic Elution/Injection volume: Change L2 = internal diameter of the column used (mm) dc1 = particle size indicated in the monograph (µm) dc2 =… Read More |
<659> PACKAGING AND STORAGE REQUIREMENTS | GENERAL DEFINITIONS/Packaging Definitions | Second Supplement to USP43–NF38 | Online | 26-Mar-2021 | 1-Dec-2025 | NA | NA | In Light-resistant container: Change 〈661.2〉, Functionality, Spectral Transmission Requirements for Light-Resistant Components and Systems. to: 〈661.2〉, Functionality Test Method, Spectral Transmission Requirements for Light-… Read More |
DOXORUBICIN HYDROCHLORIDE INJECTION | IMPURITIES/Organic Impurities | USPNF 2022 Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
DIAZOXIDE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In footnote a in Table 2: Change 7-Chloro-2H-benzothiadiazin-3(4H)-one 1,1-dioxide. to: 7-Chloro-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide. |
<251> LEAD | REQUIREMENTS FOR PROCEDURE VALIDATION | USPNF Online | Online | 27-Jan-2023 | 1-Jun-2023 | NA | NA | Change • Precision Repeatability to: • Precision |
ROSEMARY LEAF DRY AQUEOUS EXTRACT | COMPOSITION/Content of Rosmarinic Acid | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Standard solution B: Change Before injection, pass through a membrane filter of 0.45-µL or finer pore size, to: Before injection, pass through a membrane filter of 0.45-µm or finer pore size, AND In Sample solution: Change … Read More |
CALCIUM ASCORBATE | ASSAY/Procedure | USPNF Online | Online | 30-Jun-2023 | 1-Aug-2023 | NA | NA | In Analysis: Change Mr1 = molecular weight of calcium ascorbate dihydrate, 426.43 to: Mr1 = molecular weight of calcium ascorbate dihydrate, 426.34 |
AZITHROMYCIN | CHEMICAL INFORMATION | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | Change 748.98 to: 749.00 AND Change 767.00 to: 767.01 AND Change 785.02 to: 785.03 |
CEFDINIR CAPSULES | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In USP Reference Standards 〈11〉/USP Cefdinir Related Compound B RS: Change C14H13N4O4S… Read More |
METRONIDAZOLE CAPSULES | IMPURITIES | USPNF Online | Online | 31-May-2024 | 1-Jun-2024 | NA | NA | In Organic Impurities: Change Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the Assay. to: Mobile phase and Chromatographic system: Proceed as directed in the … Read More |
DOXAZOSIN MESYLATE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change CS = concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the Standard solution (mg/mL) to: CS… Read More |
ISOBUTYL ALCOHOL | ASSAY/Procedure | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change rS = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the Reference solution to: rT = sum of all the peaks except those… Read More |
RISEDRONATE SODIUM DELAYED-RELEASE TABLETS | ASSAY | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Delete [Note—Use a non-metallic liquid chromatography system for analysis.] |
ATORVASTATIN CALCIUM TABLETS | IMPURITIES/Organic Impurities | USPNF Online | Online | 30-Jun-2023 | 1-Jul-2023 | NA | NA | In Analysis: Change Mr1 = molecular weight of atorvastatin, 558.64 Mr2 = molecular weight of atorvastatin calcium, 1155.34 to: Mr1 = molecular weight of atorvastatin, 558.65 M… Read More |
AZITHROMYCIN | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Table 2: Change: 3′-N-{[4-(Acetylamino)phenyl]sulfonyl}-3′-demethylazithromycinm to: 3’-N-Demethyl-3’-N-[(4-methylphenyl)sulfonyl]azithromycinm AND In Organic Impurities… Read More |
CEFDINIR FOR ORAL SUSPENSION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In USP Reference Standards 〈11〉/USP Cefdinir Related Compound B RS: Change C14H13N4O4S… Read More |
DOCETAXEL | IMPURITIES | USPNF Online | Online | 31-May-2024 | 1-Jun-2024 | NA | NA | In Organic Impurities, Procedure 1: Change System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. to: Mobile phase, Diluent, System… Read More |
CALCIUM UNDECYLENATE | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Solution A: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.… Read More |
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF 1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL) | CHEMICAL INFORMATION | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3. |
ACARBOSE TABLETS | IDENTIFICATION/B. | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change The spectrum obtained from the Sample solution shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm–1. to: The spectrum obtained from the sample preparation shows IR maxima in the regions of 3500–3200… Read More |
<3> TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS | SPECIFIC TESTS FOR TDS | USPNF Online | Online | 28-Jul-2023 | 1-Dec-2023 | NA | NA | In Release Liner Peel Test: Change The product fails the test if the mean peel force is outside the acceptable range determined during product development. to: The product fails the test if the overall mean peel force is outside the acceptable range… Read More |
AZITHROMYCIN | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin Related Compound F RS: Change 762.97 to: 762.98 AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80 |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | APPENDICES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In two instances in Appendix 1 equations: Change 14.020 to: 14.022 |
CEFUROXIME AXETIL FOR ORAL SUSPENSION | ASSAY | USPNF Online | Online | 31-May-2024 | 1-Jun-2024 | NA | NA | In Procedure/System suitability: Change [Note—The relative retention times for acetanilide, cefuroxime axetil diastereoisomer B, cefuroxime axetil diastereoisomer A, and cefuroxime axetil delta-3 isomers are 0.4, 0.8, 0.9, and 1.0, respectively.]… Read More |
ANETHOLE | DEFINITION | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | Change (E)-1-methyl-4-(1-propenyl) benzene to: (E)-1-methoxy-4-(1-propenyl) benzene |
Methyl Acetate | CHEMICAL INFORMATION | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | Change CAS RN®: 74-20-9. to: CAS RN®: 79-20-9. |
BISOPROLOL FUMARATE | CHEMICAL INFORMATION | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change (±)-1-[[α-(2-Isoproproxyethoxy)-p-tolyl]oxy]-3-(isopropyl amino)-2-propanol fumarate (2:1) (salt) to: (±)-1-[[α-(2-Isoproproxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol fumarate (2:1) (salt) |
VALGANCICLOVIR HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Table 3/footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride. to: 3-[(2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L… Read More |
ACARBOSE | IMPURITIES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Chromatographic Purity/Analysis: Change Result = (rU/rA) × (1/F) × 100 to: Result = (rU/rA) × (1/F) |
PROCAINAMIDE HYDROCHLORIDE | ASSAY | USPNF Online | Online | 31-May-2024 | 1-Jun-2024 | NA | NA | In Resolution solution: Change p-aminoben zoic acid to: p-aminobenzoic acid |
NALOXONE HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 28-Oct-2022 | 1-Dec-2022 | NA | NA | In Limit of Naloxone Related Compound D: Delete Sensitivity solution: 1.25 µg/mL of USP Naloxone Related Compound D RS in 0.1 N hydrochloric acid AND In System suitability/Samples: Delete Sensitivity solution,… Read More |
METARAMINOL BITARTRATE | SPECIFIC TESTS/Content of Tartaric Acid | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change Result = {[(VS−VB) × N × F]/2 × W} × 100 to: Result = {[(VS−VB) × N × F]/(2 × W)} × 100 |
ISOFLURANE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Analysis: Change Result = (rU/rS) × CS × (1/F) to: Result = (rU/rS) × CF × (1/F) AND Change CS… Read More |
PURIFIED SILICEOUS EARTH | IMPURITIES | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | NA | In Leachable Arsenic/Analysis: Change A 3.0-mL portion of the Sample solution meets the requirements in Arsenic 〈211〉, Procedures, Procedure. to: A 3.0-mL portion of the Sample solution meets the… Read More |
DIGOXIN TABLETS | ASSAY | USPNF Online | Online | 29-Sep-2023 | 1-Oct-2023 | NA | NA | In Procedure/Analysis: Change CU = nominal concentration of in the Sample solution (µg/mL) to: CU = nominal concentration of digoxin in the Sample solution (µg/mL) |
GLUCAGON | PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Acetic Acid in Peptides/Analysis: Change CSPA = concentration of potassium acetate in each of the Standard solutions (mg/mL) to: CSPA = concentration of potassium acetate in each of the … Read More |
TYLOSIN INJECTION | SPECIFIC TESTS | USPNF Online | Online | 31-May-2024 | 1-Jun-2024 | NA | NA | Change pH 〈921〉 to: pH 〈791〉 |
MAGNESIUM OXIDE | IMPURITIES/Limit of Calcium | USPNF Online | Online | 25-Feb-2022 | 1-Dec-2022 | NA | NA | In Analysis: Change CU = concentration of Magnesium Hydroxide in the Sample solution (mg/mL) to: CU = concentration of Magnesium Oxide in the Sample solution (mg/mL) |
FELODIPINE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | Change Buffer, Mobile phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. to: Buffer, Mobile phase… Read More |
METARAMINOL BITARTRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards 〈11〉 | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In USP Metaraminol Enantiomer RS: Change 3-[(1S,2R)-2-Amino-1-hydroxypropyl]phenol. C9H13NO2 167.21 to: 3-[(1S,2R)-2-Amino-1-hydroxypropyl]phenol D-tartrate. C9H… Read More |
BUPIVACAINE HYDROCHLORIDE INJECTION | ASSAY/Procedure | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Chromatographic system/Column: Change 4-mm × 30-cm; packing L1 to: 3.9-mm × 30-cm; packing L1 AND In System suitability: Change [Note—The relative retention times for bupivacaine hydrochloride and dibutyl phthalate are… Read More |
REAGENTS AND REFERENCE TABLES | Reagent Specifications/Tosylchloramide Sodium | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | NA | Change 127-65-1 to: 7080-50-4 |
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 29-Sep-2023 | 1-Oct-2023 | NA | NA | In Dissolution 〈711〉/Test 8/Tolerances: Change The percentage of the labeled amount of valproic acid (C8H16O2) dissolved at the times specified conform to Dissolution <711>, Acceptance… Read More |
SECOBARBITAL SODIUM | OTHER REQUIREMENTS | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | Change Where the label states that Seco barbital Sodium is sterile, it meets the requirements for Sterility Tests 〈71〉 and for Bacterial endotoxins under Secobarbital Sodium for Injection. Where the label states that Secobarbital Sodium… Read More |
EDETATE DISODIUM COMPOUNDED OPHTHALMIC SOLUTION | DEFINITION | USPNF Online | Online | 28-Jun-2024 | 1-Jul-2024 | NA | NA | In two instances: Change to a pH between 6.5 and 7.5. to: to a pH between 6.1 and 7.1. |
<621> CHROMATOGRAPHY | SYSTEM SUITABILITY | USPNF Online | Online | 25-Mar-2022 | 1-Dec-2022 | NA | NA | Change System Repeatability—Assay of an Active Substance or an Excipient to: System Repeatability |
ZINC UNDECYLENATE | ASSAY/Procedure | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | In Solution A: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.… Read More |
FLUTICASONE PROPIONATE NASAL SPRAY | IMPURITIES/Organic Impurities | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change Samples: System suitability solution, Identification solution, and Sample solution to: Samples: Identification solution and Sample solution |
PINDOLOL | ASSAY/Procedure | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Standard stock solution: Change 1 mg/mL of USP Pindolol RS in Mobile phase prepared as follows. To a suitable amount of USP Pindolol RS add Mobile phase to fill about 90% of the total volume, and sonicate for about 5 min to… Read More |
TRIAZOLAM TABLETS | PERFORMANCE TESTS/Dissolution 〈711〉 | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | NA | In Standard solution: Change Tablet/mg to: mg/Tablet |